Clinical Concepts for Triple Therapy Use in Patients with COPD: A Delphi Consensus

References

• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Global Initiative for Chronic Obstructive Lung Disease; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed August 18, 2023.
   Google Scholar
• Miravitlles M, Kawayama T, Dreher M. LABA/LAMA as first-line therapy for COPD: a summary of the evidence and guideline recommendations. J Clin Med. 2022;11(22):6623. doi:10.3390/jcm11226623
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Calle M, Molina J, et al. Spanish COPD Guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD. Arch Bronconeumol. 2022;58(1):69–81. doi:10.1016/j.arbres.2021.03.005
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–564. doi:10.1164/rccm.202006-2618OC
   PubMed Web of Science ®Google Scholar
• Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516. doi:10.1164/rccm.201911-2207OC
   PubMed Web of Science ®Google Scholar
• Lai CC, Chen CH, Chen KH, et al. The impact of 52-week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: a systematic review and meta-analysis of randomized controlled trials. Life. 2022;12(2):173. doi:10.3390/life12020173
   PubMedGoogle Scholar
• Maltais F, Mahler DA, Pepin V, et al. Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD. Eur Respir J. 2013;42(2):539–541. doi:10.1183/09031936.00074113
   PubMed Web of Science ®Google Scholar
• Lee SD, Xie CM, Yunus F, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: a randomized, multicentre study in East Asia. Respirology. 2016;21(1):119–127. doi:10.1111/resp.12646
   PubMed Web of Science ®Google Scholar
• Jung KS, Park HY, Park SY, et al. Korean academy of tuberculosis and respiratory diseases study group; Korea chronic obstructive pulmonary disease study group. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106(3):382–389. doi:10.1016/j.rmed.2011.09.004
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Marín A, Huerta A, Carcedo D, Villacampa A, Puig-Junoy J. Estimation of the clinical and economic impact of an improvement in adherence based on the use of once-daily single-inhaler triple therapy in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1643–1654. doi:10.2147/COPD.S253567
   PubMed Web of Science ®Google Scholar
• Yu AP, Guérin A, Ponce de Leon D, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496. doi:10.3111/13696998.2011.594123
   PubMedGoogle Scholar
• Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis. 2020;15:417–438. doi:10.2147/COPD.S234823
   PubMed Web of Science ®Google Scholar
• Malerba M, Nardin M, Santini G, Mores N, Radaeli A, Montuschi P. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther Adv Respir Dis. 2018;12:1753466618760779. doi:10.1177/1753466618760779
   Web of Science ®Google Scholar
• Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022;162(5):1017–1029. doi:10.1016/j.chest.2022.06.033
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Magnussen H, Miravitlles M, Wedzicha JA. Triple therapy in COPD: what we know and what we don’t. COPD. 2017;14(6):648–662. doi:10.1080/15412555.2017.1389875
   PubMedGoogle Scholar
• Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond dual bronchodilation - triple therapy, when and why. Int J Chron Obstruct Pulmon Dis. 2022;17:165–180. doi:10.2147/COPD.S345263
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Triple inhaler versus dual bronchodilator therapy in COPD: real-world effectiveness on mortality. COPD. 2022;19(1):1–9. doi:10.1080/15412555.2021.1977789
   PubMedGoogle Scholar
• Sriprasart T, Siasoco MB, Aggarwal B, et al. The role of modeling studies in asthma management and clinical decision-making: a Delphi survey of physician knowledge and perceptions. J Asthma. 2023;7:1–15. doi:10.1080/02770903.2023.2180748
   Google Scholar
• Domingo C, Garcia G, Gemicioglu B, et al. Consensus on mild asthma management: results of a modified Delphi study. J Asthma. 2023;60(1):145–157. doi:10.1080/02770903.2022.2034850
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluña JJ, Alcázar B, Viejo JL, García-Río F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulm Pharmacol Ther. 2018;48:97–103. doi:10.1016/j.pupt.2017.10.006
   PubMed Web of Science ®Google Scholar
• Beiderbeck D, Frevel N, von der Gracht HA, Schmidt SL, Schweitzer VM. Preparing, conducting, and analyzing Delphi surveys: cross-disciplinary practices, new directions, and advancements. MethodsX. 2021;8:101401. doi:10.1016/j.mex.2021.101401
   PubMed Web of Science ®Google Scholar
• Alcázar Navarrete B, Casanova C, Miravitlles M, de Lucas P, Riesco JA, Rodríguez González-Moro JM; Working Group “Consensus document on the appropriate use of inhaled corticosteroids in COPD”. ”Correct use of inhaled corticosteroids in chronic obstructive pulmonary disease”: a consensus document. Arch Bronconeumol. 2015;51(4):193–198. doi:10.1016/j.arbres.2014.11.001
   PubMed Web of Science ®Google Scholar
• Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms, and exposure - A Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC airways working group. ERJ Open Res. 2021;7(4):00399–2021. doi:10.1183/23120541.00399-2021
   PubMedGoogle Scholar
• Monteagudo M, Barrecheguren M, Solntseva I, et al. Clinical characteristics, and factors associated with triple therapy use in newly diagnosed patients with COPD. NPJ Prim Care Respir Med. 2021;31(1):16. doi:10.1038/s41533-021-00227-x
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.9709032
   PubMed Web of Science ®Google Scholar
• Jones PW, Lamarca R, Chuecos F, et al. Characterisation, and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–1165. doi:10.1183/09031936.00038814
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Blauer-Peterson C, Buysman EK, Bengtson LGS, Paine Iii SR. Trends and characteristics of global initiative for chronic obstructive lung disease guidelines-Discordant prescribing of triple therapy among patients with COPD. Chronic Obstr Pulm Dis. 2022;9(2):135–153. doi:10.15326/jcopdf.2021.0256
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Nuñez A, Solntseva I, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol. 2021;57(3):205–213. doi:10.1016/j.arbres.2020.07.032
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177(4):396–401. doi:10.1164/rccm.200708-1290OC
   PubMed Web of Science ®Google Scholar
• Hurst JR, Han MK, Singh B, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir Res. 2022;23(1):213. doi:10.1186/s12931-022-02123-5
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855. doi:10.1016/j.chest.2019.11.007
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-5
   PubMed Web of Science ®Google Scholar
• Salvi S, Balki A, Krishnamurthy S, et al. Efficacy, and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ Open Res. 2021;7(3):00255–2021. doi:10.1183/23120541.00255-2021
   PubMedGoogle Scholar
• López-Campos JL, Alcázar Navarrete B, Riesco Miranda JA, et al. A Delphi consensus document on the use of single-inhaler fixed-dose triple therapies in COPD patients. Int J Chron Obstruct Pulmon Dis. 2020;15:1801–1811. doi:10.2147/COPD.S258818
   PubMed Web of Science ®Google Scholar
• Bogart M, Glassberg MB, Reinsch T, Stanford RH. Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respir Med. 2018;145:138–144. doi:10.1016/j.rmed.2018.10.013
   PubMed Web of Science ®Google Scholar
• Mannino D, Bogart M, Germain G, et al. Benefit of prompt versus delayed use of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) following a COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2022;17:491–504. doi:10.2147/COPD.S337668
   PubMed Web of Science ®Google Scholar
• Miravitlles M, González-Torralba F, Represas-Represas C, et al. Pulmonologists’ opinion on the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients in Spain: a cross-sectional survey. Int J Chron Obstruct Pulmon Dis. 2022;17:1577–1587. doi:10.2147/COPD.S369118
   PubMedGoogle Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids, and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(3):CD010115. doi:10.1002/14651858.CD010115.pub2
   PubMedGoogle Scholar
• European Medicines Agency; Pharmacovigilance Risk Assessment Committee (PRAC). Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD) assessment report. London, UK: European Medicines Agency; 2016. Available from: https://www.ema.europa.eu/documents/referral/inhaled-corticosteroids-article-31-referral-ema-completes-review-inhaled-corticosteroids-chronic_en.pdf. Accessed October 3, 2022.
   Google Scholar
• Hartley BF, Barnes NC, Lettis S, Compton CH, Papi A, Jones P. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2020;21(1):5. doi:10.1186/s12931-019-1262-0
   PubMed Web of Science ®Google Scholar
• Williams NP, Coombs NA, Johnson MJ, et al. Seasonality, risk factors and burden of community-acquired pneumonia in COPD patients: a population database study using linked health care records. Int J Chron Obstruct Pulmon Dis. 2017;12:313–322. doi:10.2147/COPD.S121389
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bafadhel M, Barnes NC, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:499–517. doi:10.2147/COPD.S291967
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Verhamme K, Calverley PMA, et al. A pooled analysis of mortality in patients with COPD receiving dual bronchodilation with and without additional inhaled corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545–558. doi:10.2147/COPD.S350167
   PubMed Web of Science ®Google Scholar
• Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS One. 2011;6(6):e20476. doi:10.1371/journal.pone.0020476
   PubMed Web of Science ®Google Scholar
• Thompson M. Considering the implication of variations within Delphi research. Fam Pract. 2009;26(5):420–424. doi:10.1093/fampra/cmp051
   PubMed Web of Science ®Google Scholar
• Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32(4):1008–1015.
   PubMed Web of Science ®Google Scholar
• Harding G, Leidy NK, Meddis D, Kleinman L, Wagner S, O’Brien CD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin. 2009;25(6):1563–1571. doi:10.1185/03007990902914403
   PubMed Web of Science ®Google Scholar